<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01623557</url>
  </required_header>
  <id_info>
    <org_study_id>VAC045</org_study_id>
    <nct_id>NCT01623557</nct_id>
  </id_info>
  <brief_title>A Challenge Study to Assess the Protective Efficacy of Two Malaria Vaccine Candidates</brief_title>
  <acronym>VAC045</acronym>
  <official_title>A Phase I/IIa Sporozoite Challenge Study to Assess the Protective Efficacy of Two Prime-Boost Malaria Vaccine Candidates: ChAd63 and MVA Encoding ME-TRAP and the Same Viral Vectors Encoding CS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the safety and effectiveness of four new candidate malaria
      vaccines; ChAd63 CS, ChAd63 ME-TRAP, MVA CS &amp; MVA ME-TRAP. These vaccines consist of viruses
      (ChAd63 and MVA) which have been genetically modified so (i) they cannot replicate in humans
      and (ii) they include parts of the malaria parasite; Plasmodium falciparum (CS and ME-TRAP).
      The hope is that these vaccines will induce immune responses in vaccinees that are able to
      prevent malaria.

      This proposed study will compare how effective ChAd63-MVA CS is at preventing malaria
      infection in UK volunteers following malaria challenge compared to ChAd63-MVA ME-TRAP.

      The study will be conducted at the University of Oxford's Centre for Clinical Vaccinology and
      Tropical Medicine (CCVTM), Oxford, UK and the Wellcome Trust Clinical Research Facility in
      Southampton, UK. The malaria challenge will take place at the insectary at Imperial College
      (Infection and Immunity Section) in London, UK.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effectiveness of ChAd63-MVA CS and ChAd63-MVA ME-TRAP at preventing malaria infection</measure>
    <time_frame>Up to 30 days post challenge</time_frame>
    <description>Comparison of the number of individuals who develop malaria infection between vaccinees and unvaccinated control volunteers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The safety and immunogenicity of ChAd63-MVA CS and ChAd63-MVA ME-TRAP</measure>
    <time_frame>up to 7 months post first vaccination</time_frame>
    <description>The safety of the vaccine regimens will be assessed by analysing actively and passively collected data from clinical review of volunteers and laboratory measurements.
The ability of the vaccines to induce malaria-specific immune responses (immunogenicity) will be assessed by the following laboratory tests;
(A) Interferon gamma ELISPOT. (B) Flow cytometry to measure T cell responses
Other laboratory investigations including microarray analysis may be performed.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Plasmodium Falciparum Malaria</condition>
  <arm_group>
    <arm_group_label>Group 1: ChAd63-MVA CS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 dose of ChAd63 CS 5 x 10^10 vp intramuscularly and 1 dose MVA CS 2 x 10^8 pfu intramuscularly 8 weeks later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: ChAd63-MVA ME-TRAP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 dose of ChAd63 ME-TRAP 5 x 10^10 vp intramuscularly and 1 dose MVA ME-TRAP 2 x 10^8 pfu intramuscularly 8 weeks later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Unvaccinated Infectivity Controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ChAd63-MVA CS</intervention_name>
    <description>1 dose of ChAd63 CS 5 x 10^10 vp intramuscularly and 1 dose MVA CS 2 x 10^8 pfu intramuscularly 8 weeks later.</description>
    <arm_group_label>Group 1: ChAd63-MVA CS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ChAd63-MVA ME-TRAP</intervention_name>
    <description>1 dose of ChAd63 ME-TRAP 5 x 10^10 vp intramuscularly and 1 dose MVA ME-TRAP 2 x 10^8 pfu intramuscularly 8 weeks later.</description>
    <arm_group_label>Group 2: ChAd63-MVA ME-TRAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Controlled Human Malaria Infection Administered by Mosquito Bite</intervention_name>
    <description>Approximately 3 weeks post MVA dosing</description>
    <arm_group_label>Group 1: ChAd63-MVA CS</arm_group_label>
    <arm_group_label>Group 2: ChAd63-MVA ME-TRAP</arm_group_label>
    <arm_group_label>Group 3: Unvaccinated Infectivity Controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults aged 18 to 45 years.

          -  Able and willing (in the Investigator's opinion) to comply with all study
             requirements.

          -  Willing to allow the investigators to discuss the volunteer's medical history with
             their General Practitioner.

          -  Women only: Must practice continuous effective contraception for the duration of the
             study.

          -  Agreement to refrain from blood donation during the course of the study and for at
             least 3 years after the end of their involvement in the study.

          -  Written informed consent to participate in the trial.

          -  Reachable (24/7) by mobile phone during the period between CHMI and completion of
             antimalarial treatment.

          -  Willingness to take a curative anti-malaria regimen following CHMI.

          -  For volunteers not living in Oxford: agreement to stay in a hotel room close to the
             trial centre during a part of the study (from at least day 6.5 post mosquito bite
             until anti-malarial treatment is completed).

          -  Answer all questions on the informed consent quiz correctly.

        Exclusion Criteria:

          -  History of clinical malaria (any species).

          -  Travel to a malaria endemic region during the study period or within the preceding six
             months with significant risk of malaria exposure.

          -  Use of systemic antibiotics with known antimalarial activity within 30 days of CHMI
             (e.g. trimethoprim-sulfamethoxazole, doxycycline, tetracycline, clindamycin,
             erythromycin, fluoroquinolones and azithromycin)

          -  Receipt of an investigational product in the 30 days preceding enrolment, or planned
             receipt during the study period.

          -  Prior receipt of an investigational malaria vaccine or any other investigational
             vaccine likely to impact on interpretation of the trial data.

          -  Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV
             infection; asplenia; recurrent, severe infections and chronic (more than 14 days)
             immunosuppressant medication within the past 6 months (inhaled and topical steroids
             are allowed).

          -  Use of immunoglobulins or blood products within 3 months prior to enrolment.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine (e.g. egg products, Kathon) or malaria infection.

          -  Any history of anaphylaxis post vaccination.

          -  History of clinically significant contact dermatitis.

          -  History of sickle cell anaemia, sickle cell trait, thalassemia or thalassemia trait or
             any haematological condition that could affect susceptibility to malaria infection.

          -  Pregnancy, lactation or intention to become pregnant during the study.

          -  Contraindications to the use of all three proposed anti-malarial medications;
             Malarone, Riamet and Chloroquine.

          -  History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in
             situ).

          -  History of serious psychiatric condition that may affect participation in the study.

          -  Any other serious chronic illness requiring hospital specialist supervision.

          -  Suspected or known current alcohol abuse as defined by an alcohol intake of greater
             than 42 units every week.

          -  Suspected or known injecting drug abuse in the 5 years preceding enrolment.

          -  Seropositive for hepatitis B surface antigen (HBsAg).

          -  Seropositive for hepatitis C virus (antibodies to HCV) with positive PCR for hepatitis
             C at screening.

          -  An estimated, ten year risk of fatal cardiovascular disease of â‰¥5%, as estimated by
             the Systematic Coronary Risk Evaluation (SCORE) system.76

          -  Positive family history in 1st and 2nd degree relatives &lt; 50 years old for cardiac
             disease.

          -  Volunteers unable to be closely followed for social, geographic or psychological
             reasons.

          -  Any clinically significant abnormal finding on biochemistry or haematology blood
             tests, urinalysis or clinical examination.

          -  Any other significant disease, disorder or finding which may significantly increase
             the risk to the volunteer because of participation in the study, affect the ability of
             the volunteer to participate in the study or impair interpretation of the study data.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian V S Hill, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Clinical Vaccinology and Tropical Medicine</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infection and Immunity Section, Imperial College of Science, Technology and Medicine</name>
      <address>
        <city>London</city>
        <zip>SW7 2AZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellcome Trust CRF, Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2012</study_first_submitted>
  <study_first_submitted_qc>June 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2012</study_first_posted>
  <last_update_submitted>February 12, 2015</last_update_submitted>
  <last_update_submitted_qc>February 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malaria</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Plasmodium</keyword>
  <keyword>falciparum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

